Rhineland‑Palatinate coalition faces early setbacks over voting dissent, Lotto scandal and pharma cuts

The new CDU‑SPD‑Green coalition in Rhineland‑Palatinate, led by Minister‑President Gordon Schnieder, encountered immediate challenges before his first government statement. Eight legislators abstained or voted against Schnieder’s election, marking the first sign of internal discord.

A controversy erupted over the proposed creation of a second Lotto‑Rheinland‑Pfalz managing director. After public criticism, former Landtag president Hendrik Hering declined the role, citing a loss of public trust in politics.

The state’s pharmaceutical sector also suffered a blow: U.S. drug maker Eli Lilly announced a 50 % reduction in its planned €2.5 billion Alzey injection‑facility investment, cutting the projected 1,000 jobs. Domestic pharma group Boehringer Ingelheim confirmed a €900 million spend‑down in Germany for 2027‑2030. These developments have heightened scrutiny of the new administration’s economic and health‑policy agenda.